H3B-6527

Overview

H3B-6527 is a selective FGFR4 inhibitor. It targets the FGF19–FGFR4 signaling axis, which is activated in a subset of hepatocellular carcinomas (HCC) harboring FGF19 high-level focal amplification (~6% of HCCs). Enrichment biomarker: FGF19 expression by IHC (typically ≥1% positive cells).

Evidence in the corpus

• H3B-6527 listed alongside BLU-554 and FGF401 as selective FGFR4 inhibitors requiring FGF19 IHC expression for patient enrichment in HCC; BLU-554 achieved 16% ORR in FGFR4-driven patients vs 0% in FGFR4-negative PMID:24798001.

Resistance mechanisms

Cancer types (linked)

• HCC

Sources

This page was processed by entity-page-writer on 2026-05-11.